BYND Cannasoft Adopts Innovative Approach to Address Surging Demand for Medical Cannabis in Israel Amidst Crisis
BYND Cannasoft's CRM platform plans to assist the growing demand medical cannabis industry in Israel amidst recent healthcare challenges, focusing on innovative data collection and analysis while addressing a surge in patients seeking treatment for post-trauma.
Recently, BYND Cannasoft Enterprises Inc. (BYND Cannasoft), an Israeli-based integrated software and cannabis company (1), disclosed that the establishment has a new plan of work which will target using its CRM platform to meet the growing interest for medical cannabis in Israel. The Israeli Ministry of Health has approved regulatory reforms to allow physicians to prescribe cannabis to their patients, this will be offered as a first-line treatment instead of a last resort (1). The country has witnessed the amount of licensed medical cannabis patients grow significantly, despite recent events such as the start of the war in Gaza. From this recent event, Israel has experienced an increase of more than 2,000 new patients in one month. Such a significant increase hasn’t been seen since 2021. Israel now has approximately 132,000 medical cannabis patients as of November 2023 (1). BYND Cannasoft’s CRM platform allows for small and medium-sized businesses to enhance their day-to-day operations. For example, workforce management, asset management, sales management, and contact center operations.
Through using CRM’s platform, they plan to increase data collection and analysis through innovative elements in the field of artificial intelligence (1).
According to a recent press release (1), “The Israeli medical community is experiencing a tremendous increase in the number of patients seeking treatment for post-trauma, marking a significant shift from the previous decline in this category.”
"Israel is a small country, and although we continue to take a business-as-usual approach, every one of us is directly impacted, either personally or through our family and loved ones. BYND Cannasoft supports and stands with all of the Israelis affected by this tragedy. In Israel, the cannabis and pharmaceuticals industries are part of the critical infrastructure sector, and I am very proud of how the team is coming together to work through this horrific situation," said Yftah Ben Yaackov, CEO and Director of BYND Cannasoft (1). "While we continue to develop our EZ-G device for the recreational market, and potentially as an FDA-approved medical device, our decision to refocus on cannabis will benefit our shareholders, as well as those impacted by the war who are seeking treatment from psychiatric and pain clinics. We are grateful to be in this position to help our country and its people."
In conclusion, BYND Cannasoft's strategic focus on utilizing its CRM platform to aid the growing medical cannabis sector in Israel, especially in light of recent healthcare challenges, exemplifies their commitment to contributing positively to both the industry and the nation.
Reference
- BYND Cannasoft Enterprises, Inc. Israeli Ministry of Health Reports Surge in Medical Cannabis Patients Following Recent Events https://www.globenewswire.com/news-release/2023/11/07/2775121/0/en/Israeli-Ministry-of-Health-Reports-Surge-in-Medical-Cannabis-Patients-Following-Recent-Events.html (accessed Nov 7, 2023).
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
